ALFA Filings
Every announcement, straight from the exchange
Every Transgene Biotek other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
4 announcements
The company filed a Regulation 74(5) certificate from its Registrar, confirming dematerialization activities for the quarter ended September 30, 2026.
Transgene Biotek submitted its quarterly shareholding pattern for the period ending December 2016. The company noted that certain promoter shares remain in physical form pending listing approval.
Transgene Biotek Ltd submitted a nil compliance report under Regulation 57 of SEBI LODR for the quarter ended March 31, 2026. The company confirmed it has no outstanding non-convertible securities for which interest, dividend, or principal is payable. This is a routine regulatory filing with no material financial impact.
Transgene Biotek Ltd submitted a NIL compliance report under Regulation 57(5) of SEBI LODR. The company confirmed it has no outstanding non-convertible securities and consequently no interest or principal payment obligations for the quarter ended March 31, 2026.